Baqsimi
Baqsimi is a medicine authorised by Swissmedic under authorisation number 67465. The authorisation holder is Future Health Pharma GmbH. The medicinal product code is Synthetic medicines and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 11 June 2020 and the authorisation is valid without a time limit. ATC code H04AA01 places the medicine in the group Pancreatic hormones.
| Authorisation number | 67465 |
|---|---|
| Name | Baqsimi |
| Full name | Baqsimi, Nasenpulver |
| Authorisation holder | Future Health Pharma GmbH |
| Medicinal product code | Synthetic medicines |
| Dispensing category | B · Prescription only |
| ATC code | H04AA01 |
| First authorisation | 11 June 2020 |
| Authorisation validity | unlimited |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Baqsimi, Nasenpulver | B | 11 June 2020 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 1 | Stück | H04AA01 | 07.06.3. | B |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is Baqsimi authorised in Switzerland?
Yes. Baqsimi is authorised by Swissmedic under authorisation number 67465, data as of 01 September 2026. The authorisation is valid without a time limit.
Which dispensing category does Baqsimi have?
Baqsimi is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.
Who is the authorisation holder of Baqsimi?
The authorisation holder is Future Health Pharma GmbH. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.